|
|
|
| Therapeutic effect of Tripterygium Glycosides Combined with Pancreatic Kininogenase in Treatment of Diabetic Nephropathy |
| WANG Shu-qin, WANG De-qin |
| Department of Endocrinolog,Haian Hospital, Affiliated to Nantong University, Nantong, Jiangsun 226600 |
|
|
|
|
Abstract 【Objective】To investigate the therapeutic effect of tripterygium glycosides combined pancreatic kininogenase in the treatment of diabetic nephropathy. 【Methods】A total of 80 patients of diabetic nephropathy who received therapy from March 2016 to Nov 2017 in our hospital were selected as research subjects. According to the stochastic indicator method, patients were divided into the observation group and the control group. Patients in the control group received pancreatic kininogenase treatment, while patients in the observation group received tripterygium glycosides combined with pancreatic kininogenase treatment. Clinical efficacy, levels of homocysteine (Hcy),hypersensitive C-reactive protein (hs-CRP) before and after treatment, renal function indicators (blood urea nitrogen-BUN, urinary creatinine-UCr and 24h urine protein quantification-UP) and blood glucose index (fasting blood glucose-FPG, 2h post-prandial blood sugar-2hPG and glycosylated hemoglobin-HbAlc) were compared between the two groups. The adverse reactions were also observed during treatment.【Results】The total effective rate of the observation group was 87.50%, which was significantly higher than that of the control group (67.50%).The difference between the two groups was statistically significant (P<0.05). After treatment, the levels of Hcy, hs-CRP, BUN, UCr,UP,FPG,2hPG and HbAlc in the observation group were significantly lower than those of the control group (P<0.05). One patient in the observation group had a slight increase in alanine aminoase after 1 month of treatment, and returned to normal after symptomatic treatment. No adverse reactions occurred in the control group. There was no significant difference in the incidence of adverse reactions between the observed group and the control group (P>0.05). 【Conclusion】Tripterygium glycosides combined with pancreatic kininogenase in the treatment of DN can significantly reduce serum inflammatory factors and blood glucose levels, improve renal function. It is safe and worthy of clinical application.
|
|
Received: 29 November 2017
|
|
|
|
|
|
[1] 奉雁. 缬沙坦联合硝苯地平治疗早期糖尿病肾病合并高血压的疗效[J].医学临床研究, 2013, 30(5):924-926.
[2] 张飞娟,陈晨,冯淑芝,等. 胰激肽原酶对糖尿病肾病患者肾功能及血流动力学的影响[J].山东医药,2016,56(6):73-75.
[3] Wan YG, Che XY, Sun W,et al.Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-β1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo[J].J Ethnopharmacol,2014,151(3):1079-1089.
[4] 中华医学会. 临床诊疗指南肾脏病学分册[M]. 北京:人民出版社,2011:210.
[5] 中华中医药学会肾病分会. 糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8.
[6] Mudaliar H, Pollock C, Panchapakesan U. Role of Toll-like receptors in diabetic nephropathy[J].Clin Sci (Lond),2014,126(10):685-694.
[7] 吕卫. 前列地尔联合培哚普利治疗糖尿病肾病蛋白尿的疗效分析[J].湖南师范大学学报(医学版), 2017, 14(2):183-185.
[8] 刘克锋,周霖,赵杰. 胰激肽原酶联合递法明治疗糖尿病视网膜病变的疗效观察[J].中国药房,2016,27(2):250-252.
[9] 黄静,张继强,陈峥,等. 雷公藤多苷治疗糖尿病肾病Ⅳ期患者疗效的系统评价[J].中国中药杂志,2015,40(15):3100-3109.
[10] 李萍,方莉,蔡秋萍,等. 糖尿病肾病患者微炎症和氧化应激水平及其影响因素分析[J].南京医科大学学报(自然科学版),2016,36(2):214-217.
[11] 李文宏,陈浩,翁晓春,等. 不同血液净化模式对终末期糖尿病肾病患者胰岛素抵抗及微炎症状态的影响[J].山东医药,2015,55(4):34-36.
[12] Jones SA, Fraser DJ, Fielding CA,et al.Interleukin-6 in renal disease and therapy[J].Nephrol Dial Transplant,2015,30(4):564-574.
[13] 张研,崔巍,温言,等. 2型糖尿病肾病患者血清胱抑素C和同型半胱氨酸水平的检测及其临床意义[J].吉林大学学报(医学版),2015,41(5):998-1003. |
|
|
|
2018, Vol. 35 
